hydrogen sulfide has been researched along with sulindac in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boring, D; Chattopadhyay, M; Dastagirzada, YM; Kashfi, K; Kodela, R; Nath, N; Velázquez-Martínez, CA | 1 |
| Chattopadhyay, M; Kashfi, K; Kodela, R | 1 |
2 other study(ies) available for hydrogen sulfide and sulindac
| Article | Year |
|---|---|
Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Aspirin; Cell Line, Tumor; Cell Proliferation; Growth Inhibitors; Humans; Hydrogen Sulfide; Ibuprofen; Naproxen; Sulindac; Thiones | 2012 |
NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties.
Topics: Administration, Oral; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antipyretics; Cell Line, Tumor; Cell Survival; Dinoprostone; Edema; Fever; Hydrogen Sulfide; Hyperalgesia; Male; Malondialdehyde; Nitric Oxide; Nitric Oxide Donors; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Sulindac; Superoxide Dismutase | 2015 |